Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors

Figure 1 Serum microRNA-122 level in correlation to Child-Pugh score, Barcelona clinic liver cancer stage and underlying etiology. A: Serum microRNA-122 (miR-122) level in relation to Child-Pugh score: No liver cirrhosis (n = 16), class A (n = 45), class B (n = 27), and class C (n = 3); B: Serum miR-122 level in relation to Barcelona clinic liver cancer staging system: Stage A (n = 16), stage B (n = 37), stage C (n = 32), and stage D (n = 6); C: Serum miR-122 level in relation to underlying etiology of the hepatocellular carcinoma: Alcohol abuse (n = 41), viral hepatitis (n = 12), non-alcoholic steatohepatitis (n = 13), hemochromatosis (n = 6), rare or other (n = 19). Kruskal-Wallis test and post-hoc Dunn’s test were used for statistical analysis. LC: Liver cirrhosis; NASH: Non-alcoholic steatohepatitis; BCLC: Barcelona clinic liver cancer.